Program Overview

Locally advanced or metastatic urothelial carcinoma (mUC) is an aggressive form of cancer with a poor prognosis, with a survival of 12–15 months with cisplatin-based combination chemotherapy, but only 3 to 6 months if left untreated. However, up to 50% of patients are ineligible to receive standard platinum-based treatment regimens due to the presence of comorbid conditions, and most who do receive treatment, eventually develop progressive disease. Recent developments have led to the approval of three new classes of agents that have vastly expanded treatment options for patients with mUC. With the expansion of the therapeutic armamentarium, the oncology care team is faced with interpreting a significant amount of new data, evolving guidelines, and nuanced considerations in clinic regarding practical application of these agents.

This series of CME-certified, social media-based activities will provide learners with information regarding new and evolving classes of therapies, updated guidelines in the US and EU, as well as information regarding treatment safety profiles and appropriate management of adverse events.

This activity, a X/Twitter-based How I Practice video focuses on the treatment landscape in first-, second- and subsequent-lines of therapy in metastatic disease.

Disclosure of Relevant Financial Relationships

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.